nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—bone cancer—skin cancer	0.253	0.41	CtDrD
Epirubicin—peripheral nervous system neoplasm—skin cancer	0.185	0.3	CtDrD
Epirubicin—sarcoma—skin cancer	0.178	0.289	CtDrD
Epirubicin—ABCC1—Vemurafenib—skin cancer	0.0938	0.498	CbGbCtD
Epirubicin—ABCC1—Dactinomycin—skin cancer	0.0623	0.331	CbGbCtD
Epirubicin—ABCC1—Docetaxel—skin cancer	0.0322	0.171	CbGbCtD
Epirubicin—YWHAG—Insulin-mediated glucose transport—ASIP—skin cancer	0.00265	0.114	CbGpPWpGaD
Epirubicin—CHD1—nipple—skin cancer	0.00236	0.0679	CbGeAlD
Epirubicin—DHCR7—hair follicle—skin cancer	0.00235	0.0675	CbGeAlD
Epirubicin—DHCR7—nipple—skin cancer	0.00159	0.0458	CbGeAlD
Epirubicin—YWHAG—nipple—skin cancer	0.00146	0.042	CbGeAlD
Epirubicin—AURKA—Sorafenib—Vismodegib—skin cancer	0.00141	0.604	CbGdCrCtD
Epirubicin—CHD1—mammalian vulva—skin cancer	0.00138	0.0396	CbGeAlD
Epirubicin—CHD1—lymphoid tissue—skin cancer	0.00122	0.0352	CbGeAlD
Epirubicin—CHD1—female reproductive system—skin cancer	0.00118	0.0339	CbGeAlD
Epirubicin—AURKA—mammalian vulva—skin cancer	0.00111	0.0319	CbGeAlD
Epirubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—EXOC2—skin cancer	0.00111	0.0476	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—RASA1—skin cancer	0.00109	0.047	CbGpPWpGaD
Epirubicin—PLA2G4A—nipple—skin cancer	0.00109	0.0313	CbGeAlD
Epirubicin—YWHAG—connective tissue—skin cancer	0.00104	0.0298	CbGeAlD
Epirubicin—TOP2A—nipple—skin cancer	0.00103	0.0297	CbGeAlD
Epirubicin—DHCR7—skin of body—skin cancer	0.00102	0.0293	CbGeAlD
Epirubicin—AURKA—lymphoid tissue—skin cancer	0.000986	0.0284	CbGeAlD
Epirubicin—CHD1—head—skin cancer	0.000986	0.0284	CbGeAlD
Epirubicin—AURKA—female reproductive system—skin cancer	0.000951	0.0274	CbGeAlD
Epirubicin—DHCR7—mammalian vulva—skin cancer	0.000929	0.0267	CbGeAlD
Epirubicin—ABCC1—hair follicle—skin cancer	0.000918	0.0264	CbGeAlD
Epirubicin—AURKA—Aurora B signaling—RASA1—skin cancer	0.000874	0.0376	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—skin cancer	0.000873	0.0375	CbGpPWpGaD
Epirubicin—YWHAG—mammalian vulva—skin cancer	0.000852	0.0245	CbGeAlD
Epirubicin—DHCR7—lymphoid tissue—skin cancer	0.000825	0.0237	CbGeAlD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT14—skin cancer	0.000812	0.0349	CbGpPWpGaD
Epirubicin—DHCR7—female reproductive system—skin cancer	0.000796	0.0229	CbGeAlD
Epirubicin—AURKA—head—skin cancer	0.000794	0.0229	CbGeAlD
Epirubicin—PLA2G4A—connective tissue—skin cancer	0.000772	0.0222	CbGeAlD
Epirubicin—YWHAG—lymphoid tissue—skin cancer	0.000757	0.0218	CbGeAlD
Epirubicin—YWHAG—female reproductive system—skin cancer	0.00073	0.021	CbGeAlD
Epirubicin—CHD1—lymph node—skin cancer	0.00069	0.0199	CbGeAlD
Epirubicin—DHCR7—head—skin cancer	0.000665	0.0191	CbGeAlD
Epirubicin—UGT2B7—female reproductive system—skin cancer	0.000659	0.019	CbGeAlD
Epirubicin—PLA2G4A—mammalian vulva—skin cancer	0.000636	0.0183	CbGeAlD
Epirubicin—ABCC1—nipple—skin cancer	0.000623	0.0179	CbGeAlD
Epirubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO4—skin cancer	0.000617	0.0265	CbGpPWpGaD
Epirubicin—YWHAG—head—skin cancer	0.00061	0.0175	CbGeAlD
Epirubicin—TOP2A—mammalian vulva—skin cancer	0.000604	0.0174	CbGeAlD
Epirubicin—AURKA—lymph node—skin cancer	0.000556	0.016	CbGeAlD
Epirubicin—PLA2G4A—female reproductive system—skin cancer	0.000545	0.0157	CbGeAlD
Epirubicin—TOP2A—Sorafenib—Vismodegib—skin cancer	0.000537	0.231	CbGdCrCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—XRCC3—skin cancer	0.000512	0.022	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.000511	0.022	CbGpPWpGaD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000479	0.0206	CbGpPWpGaD
Epirubicin—YWHAG—FoxO family signaling—FOXO4—skin cancer	0.000471	0.0203	CbGpPWpGaD
Epirubicin—DHCR7—lymph node—skin cancer	0.000465	0.0134	CbGeAlD
Epirubicin—YWHAG—Membrane Trafficking—EXOC2—skin cancer	0.000446	0.0192	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.000436	0.0187	CbGpPWpGaD
Epirubicin—YWHAG—lymph node—skin cancer	0.000427	0.0123	CbGeAlD
Epirubicin—PLA2G4A—PDGF Pathway—RASA1—skin cancer	0.000418	0.018	CbGpPWpGaD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—skin cancer	0.000383	0.165	CbGdCrCtD
Epirubicin—ABCC1—mammalian vulva—skin cancer	0.000364	0.0105	CbGeAlD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MSH2—skin cancer	0.00033	0.0142	CbGpPWpGaD
Epirubicin—PLA2G4A—lymph node—skin cancer	0.000319	0.00916	CbGeAlD
Epirubicin—TOP2A—lymph node—skin cancer	0.000303	0.0087	CbGeAlD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—RASA1—skin cancer	0.000292	0.0126	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—RASA1—skin cancer	0.000291	0.0125	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—RASA1—skin cancer	0.000272	0.0117	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000266	0.0114	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—FOXO4—skin cancer	0.000239	0.0103	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—skin cancer	0.000228	0.0098	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—NKX2-1—skin cancer	0.000226	0.00972	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—FOXO4—skin cancer	0.000225	0.00967	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.000213	0.00914	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—PTGS2—skin cancer	0.000208	0.00894	CbGpPWpGaD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—skin cancer	0.000205	0.00883	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—NRAS—skin cancer	0.000201	0.00862	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—BRAF—skin cancer	0.000196	0.00844	CbGpPWpGaD
Epirubicin—ABCC1—lymph node—skin cancer	0.000182	0.00524	CbGeAlD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000181	0.00776	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—KRAS—skin cancer	0.000173	0.00742	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—RASA1—skin cancer	0.000165	0.00707	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—skin cancer	0.00016	0.00686	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDK4—skin cancer	0.000157	0.00674	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—skin cancer	0.000156	0.00669	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CDK4—skin cancer	0.000151	0.00649	CbGpPWpGaD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—skin cancer	0.000147	0.00631	CbGpPWpGaD
Epirubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—skin cancer	0.000147	0.00631	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	0.000146	0.00625	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000136	0.00585	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—BRAF—skin cancer	0.000136	0.00582	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—BRAF—skin cancer	0.000134	0.00575	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—skin cancer	0.000133	0.00572	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000129	0.00555	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—BRAF—skin cancer	0.000126	0.00543	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000125	0.00535	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—NRAS—skin cancer	0.000123	0.00531	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—HRAS—skin cancer	0.000123	0.00527	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—skin cancer	0.000121	0.0052	CbGpPWpGaD
Epirubicin—PLA2G4A—Arachidonic acid metabolism—PTGS2—skin cancer	0.00012	0.00516	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—skin cancer	0.00012	0.00515	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PLIN2—skin cancer	0.000118	0.00508	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000118	0.00507	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—BRAF—skin cancer	0.000118	0.00507	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000112	0.00481	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—MLH1—skin cancer	0.000107	0.00458	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—KRAS—skin cancer	0.000106	0.00457	CbGpPWpGaD
Epirubicin—ABCC1—Arachidonic acid metabolism—PTGS2—skin cancer	9.59e-05	0.00412	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CSPG4—skin cancer	9.54e-05	0.0041	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	9.51e-05	0.00409	CbGpPWpGaD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—skin cancer	9.3e-05	0.004	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—HRAS—skin cancer	9.03e-05	0.00388	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.99e-05	0.00386	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—skin cancer	8.76e-05	0.00377	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—NRAS—skin cancer	8.52e-05	0.00366	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—HRAS—skin cancer	8.34e-05	0.00358	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MLH1—skin cancer	8.08e-05	0.00347	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—NRAS—skin cancer	7.41e-05	0.00318	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—KRAS—skin cancer	7.33e-05	0.00315	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RHOU—skin cancer	7.29e-05	0.00313	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—KRAS—skin cancer	7.23e-05	0.00311	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.18e-05	0.00309	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—BRAF—skin cancer	7.14e-05	0.00307	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—KRAS—skin cancer	6.84e-05	0.00294	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—skin cancer	6.7e-05	0.00288	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—skin cancer	6.67e-05	0.00287	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	6.64e-05	0.00285	CbGpPWpGaD
Epirubicin—Erythema—Temozolomide—skin cancer	6.49e-05	0.000482	CcSEcCtD
Epirubicin—Malnutrition—Temozolomide—skin cancer	6.49e-05	0.000482	CcSEcCtD
Epirubicin—DHCR7—Metabolism—ENO2—skin cancer	6.48e-05	0.00279	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC12A2—skin cancer	6.48e-05	0.00278	CbGpPWpGaD
Epirubicin—Breast disorder—Docetaxel—skin cancer	6.48e-05	0.000481	CcSEcCtD
Epirubicin—Discomfort—Bleomycin—skin cancer	6.47e-05	0.00048	CcSEcCtD
Epirubicin—Malaise—Dactinomycin—skin cancer	6.47e-05	0.00048	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Docetaxel—skin cancer	6.45e-05	0.000479	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Docetaxel—skin cancer	6.45e-05	0.000479	CcSEcCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—skin cancer	6.43e-05	0.00276	CbGpPWpGaD
Epirubicin—Leukopenia—Dactinomycin—skin cancer	6.42e-05	0.000477	CcSEcCtD
Epirubicin—Nasopharyngitis—Docetaxel—skin cancer	6.41e-05	0.000476	CcSEcCtD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—KRAS—skin cancer	6.38e-05	0.00274	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—CDK4—skin cancer	6.37e-05	0.00274	CbGpPWpGaD
Epirubicin—Dysgeusia—Temozolomide—skin cancer	6.35e-05	0.000472	CcSEcCtD
Epirubicin—Asthenia—Imiquimod—skin cancer	6.34e-05	0.000471	CcSEcCtD
Epirubicin—Confusional state—Bleomycin—skin cancer	6.33e-05	0.00047	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Docetaxel—skin cancer	6.32e-05	0.000469	CcSEcCtD
Epirubicin—Oedema—Bleomycin—skin cancer	6.28e-05	0.000466	CcSEcCtD
Epirubicin—Anaphylactic shock—Bleomycin—skin cancer	6.28e-05	0.000466	CcSEcCtD
Epirubicin—Back pain—Temozolomide—skin cancer	6.28e-05	0.000466	CcSEcCtD
Epirubicin—Pruritus—Imiquimod—skin cancer	6.25e-05	0.000464	CcSEcCtD
Epirubicin—Infection—Bleomycin—skin cancer	6.24e-05	0.000463	CcSEcCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—HRAS—skin cancer	6.23e-05	0.00268	CbGpPWpGaD
Epirubicin—Dysphagia—Docetaxel—skin cancer	6.19e-05	0.00046	CcSEcCtD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	6.16e-05	0.00265	CbGpPWpGaD
Epirubicin—Nausea—Vemurafenib—skin cancer	6.15e-05	0.000457	CcSEcCtD
Epirubicin—Thrombocytopenia—Bleomycin—skin cancer	6.15e-05	0.000456	CcSEcCtD
Epirubicin—Arrhythmia—Fluorouracil—skin cancer	6.14e-05	0.000456	CcSEcCtD
Epirubicin—Vision blurred—Temozolomide—skin cancer	6.12e-05	0.000454	CcSEcCtD
Epirubicin—Myalgia—Dactinomycin—skin cancer	6.11e-05	0.000454	CcSEcCtD
Epirubicin—Alopecia—Fluorouracil—skin cancer	6.07e-05	0.000451	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDK4—skin cancer	6.06e-05	0.00261	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TERT—skin cancer	6.06e-05	0.0026	CbGpPWpGaD
Epirubicin—Diarrhoea—Imiquimod—skin cancer	6.05e-05	0.000449	CcSEcCtD
Epirubicin—Discomfort—Dactinomycin—skin cancer	6.03e-05	0.000448	CcSEcCtD
Epirubicin—Angina pectoris—Docetaxel—skin cancer	6.03e-05	0.000448	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PTCH2—skin cancer	6.03e-05	0.00259	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Temozolomide—skin cancer	6.02e-05	0.000447	CcSEcCtD
Epirubicin—Anaemia—Temozolomide—skin cancer	6e-05	0.000445	CcSEcCtD
Epirubicin—Anorexia—Bleomycin—skin cancer	5.98e-05	0.000444	CcSEcCtD
Epirubicin—Erythema—Fluorouracil—skin cancer	5.98e-05	0.000444	CcSEcCtD
Epirubicin—Agitation—Temozolomide—skin cancer	5.96e-05	0.000443	CcSEcCtD
Epirubicin—Pancytopenia—Docetaxel—skin cancer	5.88e-05	0.000437	CcSEcCtD
Epirubicin—Hypotension—Bleomycin—skin cancer	5.87e-05	0.000436	CcSEcCtD
Epirubicin—Oedema—Dactinomycin—skin cancer	5.86e-05	0.000435	CcSEcCtD
Epirubicin—Malaise—Temozolomide—skin cancer	5.85e-05	0.000434	CcSEcCtD
Epirubicin—Dizziness—Imiquimod—skin cancer	5.84e-05	0.000434	CcSEcCtD
Epirubicin—Vertigo—Temozolomide—skin cancer	5.83e-05	0.000433	CcSEcCtD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	5.83e-05	0.00251	CbGpPWpGaD
Epirubicin—Infection—Dactinomycin—skin cancer	5.82e-05	0.000432	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—HRAS—skin cancer	5.81e-05	0.0025	CbGpPWpGaD
Epirubicin—Leukopenia—Temozolomide—skin cancer	5.81e-05	0.000431	CcSEcCtD
Epirubicin—Neutropenia—Docetaxel—skin cancer	5.79e-05	0.00043	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.75e-05	0.00247	CbGpPWpGaD
Epirubicin—Palpitations—Temozolomide—skin cancer	5.73e-05	0.000426	CcSEcCtD
Epirubicin—Thrombocytopenia—Dactinomycin—skin cancer	5.73e-05	0.000426	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Bleomycin—skin cancer	5.72e-05	0.000425	CcSEcCtD
Epirubicin—PLA2G4A—Endothelins—HRAS—skin cancer	5.68e-05	0.00244	CbGpPWpGaD
Epirubicin—Cough—Temozolomide—skin cancer	5.66e-05	0.00042	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MLH1—skin cancer	5.65e-05	0.00243	CbGpPWpGaD
Epirubicin—Paraesthesia—Bleomycin—skin cancer	5.64e-05	0.000419	CcSEcCtD
Epirubicin—Weight increased—Docetaxel—skin cancer	5.64e-05	0.000418	CcSEcCtD
Epirubicin—Vision blurred—Fluorouracil—skin cancer	5.63e-05	0.000418	CcSEcCtD
Epirubicin—Convulsion—Temozolomide—skin cancer	5.62e-05	0.000417	CcSEcCtD
Epirubicin—Vomiting—Imiquimod—skin cancer	5.62e-05	0.000417	CcSEcCtD
Epirubicin—Weight decreased—Docetaxel—skin cancer	5.6e-05	0.000416	CcSEcCtD
Epirubicin—Hypertension—Temozolomide—skin cancer	5.6e-05	0.000416	CcSEcCtD
Epirubicin—Dyspnoea—Bleomycin—skin cancer	5.6e-05	0.000416	CcSEcCtD
Epirubicin—Anorexia—Dactinomycin—skin cancer	5.58e-05	0.000414	CcSEcCtD
Epirubicin—Rash—Imiquimod—skin cancer	5.57e-05	0.000414	CcSEcCtD
Epirubicin—Dermatitis—Imiquimod—skin cancer	5.57e-05	0.000413	CcSEcCtD
Epirubicin—Pneumonia—Docetaxel—skin cancer	5.55e-05	0.000412	CcSEcCtD
Epirubicin—Headache—Imiquimod—skin cancer	5.54e-05	0.000411	CcSEcCtD
Epirubicin—Anaemia—Fluorouracil—skin cancer	5.53e-05	0.00041	CcSEcCtD
Epirubicin—Arthralgia—Temozolomide—skin cancer	5.52e-05	0.00041	CcSEcCtD
Epirubicin—Myalgia—Temozolomide—skin cancer	5.52e-05	0.00041	CcSEcCtD
Epirubicin—Infestation NOS—Docetaxel—skin cancer	5.52e-05	0.00041	CcSEcCtD
Epirubicin—Infestation—Docetaxel—skin cancer	5.52e-05	0.00041	CcSEcCtD
Epirubicin—Anxiety—Temozolomide—skin cancer	5.51e-05	0.000409	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	5.49e-05	0.000407	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Docetaxel—skin cancer	5.47e-05	0.000406	CcSEcCtD
Epirubicin—Discomfort—Temozolomide—skin cancer	5.46e-05	0.000405	CcSEcCtD
Epirubicin—Decreased appetite—Bleomycin—skin cancer	5.46e-05	0.000405	CcSEcCtD
Epirubicin—Renal failure—Docetaxel—skin cancer	5.43e-05	0.000403	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CDK4—skin cancer	5.42e-05	0.00233	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—skin cancer	5.42e-05	0.00233	CbGpPWpGaD
Epirubicin—Neuropathy peripheral—Docetaxel—skin cancer	5.41e-05	0.000402	CcSEcCtD
Epirubicin—Dry mouth—Temozolomide—skin cancer	5.4e-05	0.000401	CcSEcCtD
Epirubicin—Stomatitis—Docetaxel—skin cancer	5.38e-05	0.0004	CcSEcCtD
Epirubicin—Jaundice—Docetaxel—skin cancer	5.38e-05	0.0004	CcSEcCtD
Epirubicin—Pain—Bleomycin—skin cancer	5.37e-05	0.000399	CcSEcCtD
Epirubicin—Conjunctivitis—Docetaxel—skin cancer	5.37e-05	0.000399	CcSEcCtD
Epirubicin—Leukopenia—Fluorouracil—skin cancer	5.35e-05	0.000397	CcSEcCtD
Epirubicin—Confusional state—Temozolomide—skin cancer	5.34e-05	0.000396	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Dactinomycin—skin cancer	5.33e-05	0.000396	CcSEcCtD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—skin cancer	5.3e-05	0.00228	CbGpPWpGaD
Epirubicin—Oedema—Temozolomide—skin cancer	5.3e-05	0.000393	CcSEcCtD
Epirubicin—Anaphylactic shock—Temozolomide—skin cancer	5.3e-05	0.000393	CcSEcCtD
Epirubicin—Infection—Temozolomide—skin cancer	5.26e-05	0.000391	CcSEcCtD
Epirubicin—Nausea—Imiquimod—skin cancer	5.25e-05	0.00039	CcSEcCtD
Epirubicin—Hepatobiliary disease—Docetaxel—skin cancer	5.22e-05	0.000388	CcSEcCtD
Epirubicin—Epistaxis—Docetaxel—skin cancer	5.21e-05	0.000387	CcSEcCtD
Epirubicin—Nervous system disorder—Temozolomide—skin cancer	5.19e-05	0.000386	CcSEcCtD
Epirubicin—Thrombocytopenia—Temozolomide—skin cancer	5.19e-05	0.000385	CcSEcCtD
Epirubicin—Convulsion—Fluorouracil—skin cancer	5.18e-05	0.000385	CcSEcCtD
Epirubicin—Feeling abnormal—Bleomycin—skin cancer	5.17e-05	0.000384	CcSEcCtD
Epirubicin—Agranulocytosis—Docetaxel—skin cancer	5.15e-05	0.000383	CcSEcCtD
Epirubicin—Skin disorder—Temozolomide—skin cancer	5.14e-05	0.000382	CcSEcCtD
Epirubicin—Hyperhidrosis—Temozolomide—skin cancer	5.12e-05	0.00038	CcSEcCtD
Epirubicin—Chest pain—Fluorouracil—skin cancer	5.09e-05	0.000378	CcSEcCtD
Epirubicin—Myalgia—Fluorouracil—skin cancer	5.09e-05	0.000378	CcSEcCtD
Epirubicin—Decreased appetite—Dactinomycin—skin cancer	5.09e-05	0.000378	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.07e-05	0.00218	CbGpPWpGaD
Epirubicin—Fatigue—Dactinomycin—skin cancer	5.05e-05	0.000375	CcSEcCtD
Epirubicin—Anorexia—Temozolomide—skin cancer	5.05e-05	0.000375	CcSEcCtD
Epirubicin—Discomfort—Fluorouracil—skin cancer	5.03e-05	0.000373	CcSEcCtD
Epirubicin—Pain—Dactinomycin—skin cancer	5.01e-05	0.000372	CcSEcCtD
Epirubicin—Urticaria—Bleomycin—skin cancer	4.99e-05	0.00037	CcSEcCtD
Epirubicin—Haemoglobin—Docetaxel—skin cancer	4.98e-05	0.00037	CcSEcCtD
Epirubicin—Rhinitis—Docetaxel—skin cancer	4.97e-05	0.000369	CcSEcCtD
Epirubicin—Body temperature increased—Bleomycin—skin cancer	4.96e-05	0.000368	CcSEcCtD
Epirubicin—Haemorrhage—Docetaxel—skin cancer	4.96e-05	0.000368	CcSEcCtD
Epirubicin—Hepatitis—Docetaxel—skin cancer	4.96e-05	0.000368	CcSEcCtD
Epirubicin—Hypoaesthesia—Docetaxel—skin cancer	4.93e-05	0.000366	CcSEcCtD
Epirubicin—Confusional state—Fluorouracil—skin cancer	4.92e-05	0.000365	CcSEcCtD
Epirubicin—Pharyngitis—Docetaxel—skin cancer	4.92e-05	0.000365	CcSEcCtD
Epirubicin—Urinary tract disorder—Docetaxel—skin cancer	4.9e-05	0.000363	CcSEcCtD
Epirubicin—Oedema peripheral—Docetaxel—skin cancer	4.88e-05	0.000363	CcSEcCtD
Epirubicin—Oedema—Fluorouracil—skin cancer	4.88e-05	0.000362	CcSEcCtD
Epirubicin—Anaphylactic shock—Fluorouracil—skin cancer	4.88e-05	0.000362	CcSEcCtD
Epirubicin—Connective tissue disorder—Docetaxel—skin cancer	4.87e-05	0.000362	CcSEcCtD
Epirubicin—Urethral disorder—Docetaxel—skin cancer	4.86e-05	0.000361	CcSEcCtD
Epirubicin—Infection—Fluorouracil—skin cancer	4.85e-05	0.00036	CcSEcCtD
Epirubicin—Feeling abnormal—Dactinomycin—skin cancer	4.82e-05	0.000358	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Temozolomide—skin cancer	4.82e-05	0.000358	CcSEcCtD
Epirubicin—Insomnia—Temozolomide—skin cancer	4.79e-05	0.000356	CcSEcCtD
Epirubicin—Gastrointestinal pain—Dactinomycin—skin cancer	4.79e-05	0.000356	CcSEcCtD
Epirubicin—Nervous system disorder—Fluorouracil—skin cancer	4.79e-05	0.000355	CcSEcCtD
Epirubicin—Thrombocytopenia—Fluorouracil—skin cancer	4.78e-05	0.000355	CcSEcCtD
Epirubicin—Visual impairment—Docetaxel—skin cancer	4.78e-05	0.000355	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—TP53—skin cancer	4.77e-05	0.00205	CbGpPWpGaD
Epirubicin—Tachycardia—Fluorouracil—skin cancer	4.76e-05	0.000354	CcSEcCtD
Epirubicin—Paraesthesia—Temozolomide—skin cancer	4.76e-05	0.000353	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.74e-05	0.00204	CbGpPWpGaD
Epirubicin—Dyspnoea—Temozolomide—skin cancer	4.72e-05	0.000351	CcSEcCtD
Epirubicin—Somnolence—Temozolomide—skin cancer	4.71e-05	0.00035	CcSEcCtD
Epirubicin—Erythema multiforme—Docetaxel—skin cancer	4.69e-05	0.000348	CcSEcCtD
Epirubicin—Dyspepsia—Temozolomide—skin cancer	4.66e-05	0.000346	CcSEcCtD
Epirubicin—Anorexia—Fluorouracil—skin cancer	4.65e-05	0.000345	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDKN2A—skin cancer	4.63e-05	0.00199	CbGpPWpGaD
Epirubicin—Eye disorder—Docetaxel—skin cancer	4.63e-05	0.000344	CcSEcCtD
Epirubicin—Abdominal pain—Dactinomycin—skin cancer	4.63e-05	0.000344	CcSEcCtD
Epirubicin—Body temperature increased—Dactinomycin—skin cancer	4.63e-05	0.000344	CcSEcCtD
Epirubicin—Hypersensitivity—Bleomycin—skin cancer	4.63e-05	0.000343	CcSEcCtD
Epirubicin—Decreased appetite—Temozolomide—skin cancer	4.6e-05	0.000342	CcSEcCtD
Epirubicin—Cardiac disorder—Docetaxel—skin cancer	4.6e-05	0.000342	CcSEcCtD
Epirubicin—Flushing—Docetaxel—skin cancer	4.6e-05	0.000342	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDK4—skin cancer	4.59e-05	0.00197	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TERT—skin cancer	4.59e-05	0.00197	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Temozolomide—skin cancer	4.57e-05	0.000339	CcSEcCtD
Epirubicin—Fatigue—Temozolomide—skin cancer	4.57e-05	0.000339	CcSEcCtD
Epirubicin—Hypotension—Fluorouracil—skin cancer	4.56e-05	0.000339	CcSEcCtD
Epirubicin—Constipation—Temozolomide—skin cancer	4.53e-05	0.000336	CcSEcCtD
Epirubicin—Pain—Temozolomide—skin cancer	4.53e-05	0.000336	CcSEcCtD
Epirubicin—Asthenia—Bleomycin—skin cancer	4.5e-05	0.000334	CcSEcCtD
Epirubicin—Angiopathy—Docetaxel—skin cancer	4.5e-05	0.000334	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—NRAS—skin cancer	4.49e-05	0.00193	CbGpPWpGaD
Epirubicin—Immune system disorder—Docetaxel—skin cancer	4.48e-05	0.000332	CcSEcCtD
Epirubicin—Mediastinal disorder—Docetaxel—skin cancer	4.47e-05	0.000332	CcSEcCtD
Epirubicin—Chills—Docetaxel—skin cancer	4.45e-05	0.00033	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Fluorouracil—skin cancer	4.45e-05	0.00033	CcSEcCtD
Epirubicin—Pruritus—Bleomycin—skin cancer	4.44e-05	0.00033	CcSEcCtD
Epirubicin—Arrhythmia—Docetaxel—skin cancer	4.43e-05	0.000329	CcSEcCtD
Epirubicin—Insomnia—Fluorouracil—skin cancer	4.41e-05	0.000328	CcSEcCtD
Epirubicin—Paraesthesia—Fluorouracil—skin cancer	4.38e-05	0.000325	CcSEcCtD
Epirubicin—Alopecia—Docetaxel—skin cancer	4.38e-05	0.000325	CcSEcCtD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	4.37e-05	0.00188	CbGpPWpGaD
Epirubicin—Feeling abnormal—Temozolomide—skin cancer	4.36e-05	0.000324	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—MC1R—skin cancer	4.36e-05	0.00187	CbGpPWpGaD
Epirubicin—Dyspnoea—Fluorouracil—skin cancer	4.35e-05	0.000323	CcSEcCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL6—skin cancer	4.34e-05	0.00187	CbGpPWpGaD
Epirubicin—Mental disorder—Docetaxel—skin cancer	4.34e-05	0.000322	CcSEcCtD
Epirubicin—Somnolence—Fluorouracil—skin cancer	4.34e-05	0.000322	CcSEcCtD
Epirubicin—Gastrointestinal pain—Temozolomide—skin cancer	4.33e-05	0.000322	CcSEcCtD
Epirubicin—Erythema—Docetaxel—skin cancer	4.32e-05	0.00032	CcSEcCtD
Epirubicin—Malnutrition—Docetaxel—skin cancer	4.32e-05	0.00032	CcSEcCtD
Epirubicin—Hypersensitivity—Dactinomycin—skin cancer	4.31e-05	0.00032	CcSEcCtD
Epirubicin—Dyspepsia—Fluorouracil—skin cancer	4.3e-05	0.000319	CcSEcCtD
Epirubicin—Decreased appetite—Fluorouracil—skin cancer	4.24e-05	0.000315	CcSEcCtD
Epirubicin—Dysgeusia—Docetaxel—skin cancer	4.23e-05	0.000314	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Fluorouracil—skin cancer	4.21e-05	0.000313	CcSEcCtD
Epirubicin—Urticaria—Temozolomide—skin cancer	4.21e-05	0.000312	CcSEcCtD
Epirubicin—Asthenia—Dactinomycin—skin cancer	4.2e-05	0.000312	CcSEcCtD
Epirubicin—Body temperature increased—Temozolomide—skin cancer	4.19e-05	0.000311	CcSEcCtD
Epirubicin—Abdominal pain—Temozolomide—skin cancer	4.19e-05	0.000311	CcSEcCtD
Epirubicin—Back pain—Docetaxel—skin cancer	4.17e-05	0.00031	CcSEcCtD
Epirubicin—Pain—Fluorouracil—skin cancer	4.17e-05	0.00031	CcSEcCtD
Epirubicin—Muscle spasms—Docetaxel—skin cancer	4.15e-05	0.000308	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—CDKN2A—skin cancer	4.14e-05	0.00178	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.11e-05	0.00177	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDK4—skin cancer	4.11e-05	0.00177	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PLIN2—skin cancer	4.08e-05	0.00175	CbGpPWpGaD
Epirubicin—Feeling abnormal—Fluorouracil—skin cancer	4.02e-05	0.000299	CcSEcCtD
Epirubicin—Diarrhoea—Dactinomycin—skin cancer	4.01e-05	0.000297	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—PLIN2—skin cancer	4e-05	0.00172	CbGpPWpGaD
Epirubicin—Vomiting—Bleomycin—skin cancer	3.99e-05	0.000296	CcSEcCtD
Epirubicin—Anaemia—Docetaxel—skin cancer	3.99e-05	0.000296	CcSEcCtD
Epirubicin—Rash—Bleomycin—skin cancer	3.96e-05	0.000294	CcSEcCtD
Epirubicin—Dermatitis—Bleomycin—skin cancer	3.95e-05	0.000294	CcSEcCtD
Epirubicin—Hypersensitivity—Temozolomide—skin cancer	3.9e-05	0.00029	CcSEcCtD
Epirubicin—Urticaria—Fluorouracil—skin cancer	3.88e-05	0.000288	CcSEcCtD
Epirubicin—Syncope—Docetaxel—skin cancer	3.87e-05	0.000287	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—KRAS—skin cancer	3.86e-05	0.00166	CbGpPWpGaD
Epirubicin—Leukopenia—Docetaxel—skin cancer	3.86e-05	0.000287	CcSEcCtD
Epirubicin—Body temperature increased—Fluorouracil—skin cancer	3.86e-05	0.000286	CcSEcCtD
Epirubicin—Palpitations—Docetaxel—skin cancer	3.81e-05	0.000283	CcSEcCtD
Epirubicin—Asthenia—Temozolomide—skin cancer	3.8e-05	0.000282	CcSEcCtD
Epirubicin—Loss of consciousness—Docetaxel—skin cancer	3.79e-05	0.000282	CcSEcCtD
Epirubicin—Cough—Docetaxel—skin cancer	3.77e-05	0.00028	CcSEcCtD
Epirubicin—DHCR7—Metabolism—ERCC2—skin cancer	3.76e-05	0.00162	CbGpPWpGaD
Epirubicin—Pruritus—Temozolomide—skin cancer	3.75e-05	0.000278	CcSEcCtD
Epirubicin—Convulsion—Docetaxel—skin cancer	3.74e-05	0.000278	CcSEcCtD
Epirubicin—Nausea—Bleomycin—skin cancer	3.73e-05	0.000277	CcSEcCtD
Epirubicin—Hypertension—Docetaxel—skin cancer	3.73e-05	0.000277	CcSEcCtD
Epirubicin—Vomiting—Dactinomycin—skin cancer	3.72e-05	0.000276	CcSEcCtD
Epirubicin—Rash—Dactinomycin—skin cancer	3.69e-05	0.000274	CcSEcCtD
Epirubicin—Chest pain—Docetaxel—skin cancer	3.67e-05	0.000273	CcSEcCtD
Epirubicin—Myalgia—Docetaxel—skin cancer	3.67e-05	0.000273	CcSEcCtD
Epirubicin—Arthralgia—Docetaxel—skin cancer	3.67e-05	0.000273	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.65e-05	0.000271	CcSEcCtD
Epirubicin—Diarrhoea—Temozolomide—skin cancer	3.62e-05	0.000269	CcSEcCtD
Epirubicin—Hypersensitivity—Fluorouracil—skin cancer	3.59e-05	0.000267	CcSEcCtD
Epirubicin—Dry mouth—Docetaxel—skin cancer	3.59e-05	0.000267	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PTCH2—skin cancer	3.56e-05	0.00153	CbGpPWpGaD
Epirubicin—Confusional state—Docetaxel—skin cancer	3.55e-05	0.000264	CcSEcCtD
Epirubicin—Anaphylactic shock—Docetaxel—skin cancer	3.52e-05	0.000261	CcSEcCtD
Epirubicin—Oedema—Docetaxel—skin cancer	3.52e-05	0.000261	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—skin cancer	3.51e-05	0.00151	CbGpPWpGaD
Epirubicin—Dizziness—Temozolomide—skin cancer	3.5e-05	0.00026	CcSEcCtD
Epirubicin—Infection—Docetaxel—skin cancer	3.5e-05	0.00026	CcSEcCtD
Epirubicin—Nausea—Dactinomycin—skin cancer	3.48e-05	0.000258	CcSEcCtD
Epirubicin—Shock—Docetaxel—skin cancer	3.46e-05	0.000257	CcSEcCtD
Epirubicin—Nervous system disorder—Docetaxel—skin cancer	3.45e-05	0.000256	CcSEcCtD
Epirubicin—Pruritus—Fluorouracil—skin cancer	3.45e-05	0.000256	CcSEcCtD
Epirubicin—Thrombocytopenia—Docetaxel—skin cancer	3.45e-05	0.000256	CcSEcCtD
Epirubicin—Tachycardia—Docetaxel—skin cancer	3.44e-05	0.000255	CcSEcCtD
Epirubicin—Skin disorder—Docetaxel—skin cancer	3.42e-05	0.000254	CcSEcCtD
Epirubicin—Vomiting—Temozolomide—skin cancer	3.37e-05	0.00025	CcSEcCtD
Epirubicin—Anorexia—Docetaxel—skin cancer	3.36e-05	0.000249	CcSEcCtD
Epirubicin—Rash—Temozolomide—skin cancer	3.34e-05	0.000248	CcSEcCtD
Epirubicin—Diarrhoea—Fluorouracil—skin cancer	3.34e-05	0.000248	CcSEcCtD
Epirubicin—Dermatitis—Temozolomide—skin cancer	3.34e-05	0.000248	CcSEcCtD
Epirubicin—Headache—Temozolomide—skin cancer	3.32e-05	0.000246	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CSPG4—skin cancer	3.29e-05	0.00141	CbGpPWpGaD
Epirubicin—Hypotension—Docetaxel—skin cancer	3.29e-05	0.000244	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—skin cancer	3.28e-05	0.00141	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CSPG4—skin cancer	3.23e-05	0.00139	CbGpPWpGaD
Epirubicin—Dizziness—Fluorouracil—skin cancer	3.23e-05	0.00024	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDK4—skin cancer	3.21e-05	0.00138	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TERT—skin cancer	3.21e-05	0.00138	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Docetaxel—skin cancer	3.21e-05	0.000238	CcSEcCtD
Epirubicin—ABCC1—Metabolism—PLIN2—skin cancer	3.2e-05	0.00138	CbGpPWpGaD
Epirubicin—Insomnia—Docetaxel—skin cancer	3.19e-05	0.000237	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.18e-05	0.00137	CbGpPWpGaD
Epirubicin—Paraesthesia—Docetaxel—skin cancer	3.16e-05	0.000235	CcSEcCtD
Epirubicin—Nausea—Temozolomide—skin cancer	3.15e-05	0.000234	CcSEcCtD
Epirubicin—Dyspnoea—Docetaxel—skin cancer	3.14e-05	0.000233	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—skin cancer	3.14e-05	0.00135	CbGpPWpGaD
Epirubicin—Somnolence—Docetaxel—skin cancer	3.13e-05	0.000232	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—SHH—skin cancer	3.11e-05	0.00133	CbGpPWpGaD
Epirubicin—Vomiting—Fluorouracil—skin cancer	3.1e-05	0.00023	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—skin cancer	3.1e-05	0.00023	CcSEcCtD
Epirubicin—ABCC1—Disease—CSPG4—skin cancer	3.08e-05	0.00132	CbGpPWpGaD
Epirubicin—Rash—Fluorouracil—skin cancer	3.08e-05	0.000228	CcSEcCtD
Epirubicin—Dermatitis—Fluorouracil—skin cancer	3.07e-05	0.000228	CcSEcCtD
Epirubicin—Decreased appetite—Docetaxel—skin cancer	3.06e-05	0.000227	CcSEcCtD
Epirubicin—Headache—Fluorouracil—skin cancer	3.06e-05	0.000227	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—skin cancer	3.04e-05	0.000226	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—skin cancer	3.04e-05	0.000225	CcSEcCtD
Epirubicin—Constipation—Docetaxel—skin cancer	3.01e-05	0.000224	CcSEcCtD
Epirubicin—Pain—Docetaxel—skin cancer	3.01e-05	0.000224	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PTCH1—skin cancer	2.94e-05	0.00127	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—SMO—skin cancer	2.94e-05	0.00127	CbGpPWpGaD
Epirubicin—Feeling abnormal—Docetaxel—skin cancer	2.9e-05	0.000215	CcSEcCtD
Epirubicin—Nausea—Fluorouracil—skin cancer	2.9e-05	0.000215	CcSEcCtD
Epirubicin—Gastrointestinal pain—Docetaxel—skin cancer	2.88e-05	0.000214	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDK4—skin cancer	2.87e-05	0.00123	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PTGER4—skin cancer	2.87e-05	0.00123	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.82e-05	0.00121	CbGpPWpGaD
Epirubicin—Abdominal pain—Docetaxel—skin cancer	2.78e-05	0.000207	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—skin cancer	2.78e-05	0.000207	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.75e-05	0.00118	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—skin cancer	2.71e-05	0.00116	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GLI2—skin cancer	2.7e-05	0.00116	CbGpPWpGaD
Epirubicin—Hypersensitivity—Docetaxel—skin cancer	2.59e-05	0.000193	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CSPG4—skin cancer	2.58e-05	0.00111	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MC1R—skin cancer	2.57e-05	0.00111	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GLI1—skin cancer	2.54e-05	0.00109	CbGpPWpGaD
Epirubicin—Asthenia—Docetaxel—skin cancer	2.53e-05	0.000188	CcSEcCtD
Epirubicin—Pruritus—Docetaxel—skin cancer	2.49e-05	0.000185	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—IL6—skin cancer	2.48e-05	0.00107	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.46e-05	0.00106	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.45e-05	0.00105	CbGpPWpGaD
Epirubicin—Diarrhoea—Docetaxel—skin cancer	2.41e-05	0.000179	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SUFU—skin cancer	2.41e-05	0.00103	CbGpPWpGaD
Epirubicin—Dizziness—Docetaxel—skin cancer	2.33e-05	0.000173	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—skin cancer	2.31e-05	0.000991	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTGS2—skin cancer	2.26e-05	0.00097	CbGpPWpGaD
Epirubicin—Vomiting—Docetaxel—skin cancer	2.24e-05	0.000166	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ENO2—skin cancer	2.24e-05	0.000962	CbGpPWpGaD
Epirubicin—Rash—Docetaxel—skin cancer	2.22e-05	0.000165	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—skin cancer	2.22e-05	0.000165	CcSEcCtD
Epirubicin—Headache—Docetaxel—skin cancer	2.21e-05	0.000164	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDKN2A—skin cancer	2.2e-05	0.000944	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ENO2—skin cancer	2.19e-05	0.000943	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SHH—skin cancer	2.09e-05	0.0009	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ENO2—skin cancer	2.09e-05	0.0009	CbGpPWpGaD
Epirubicin—Nausea—Docetaxel—skin cancer	2.09e-05	0.000155	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SHH—skin cancer	1.83e-05	0.000788	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RASA1—skin cancer	1.82e-05	0.000784	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ENO2—skin cancer	1.75e-05	0.000753	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—skin cancer	1.75e-05	0.000751	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMO—skin cancer	1.74e-05	0.000747	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTCH1—skin cancer	1.74e-05	0.000747	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.72e-05	0.000737	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FOXO4—skin cancer	1.71e-05	0.000733	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTGER4—skin cancer	1.69e-05	0.000728	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO4—skin cancer	1.5e-05	0.000643	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—NRAS—skin cancer	1.47e-05	0.00063	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.37e-05	0.000589	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ERCC2—skin cancer	1.3e-05	0.000559	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ERCC2—skin cancer	1.27e-05	0.000548	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—skin cancer	1.26e-05	0.000542	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—skin cancer	1.22e-05	0.000525	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERCC2—skin cancer	1.22e-05	0.000523	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—skin cancer	1.14e-05	0.00049	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—skin cancer	1.12e-05	0.000482	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—skin cancer	1.07e-05	0.000461	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ERCC2—skin cancer	1.02e-05	0.000438	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—skin cancer	9.99e-06	0.000429	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—skin cancer	9.03e-06	0.000388	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—skin cancer	8.42e-06	0.000362	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—skin cancer	7.91e-06	0.00034	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—skin cancer	7.79e-06	0.000335	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—skin cancer	7.64e-06	0.000328	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—skin cancer	7.29e-06	0.000313	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—skin cancer	7.24e-06	0.000311	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—skin cancer	6.16e-06	0.000265	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—skin cancer	6.11e-06	0.000262	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—skin cancer	5.89e-06	0.000253	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—skin cancer	5.67e-06	0.000244	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—skin cancer	4.97e-06	0.000214	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—skin cancer	4.88e-06	0.00021	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—skin cancer	4.28e-06	0.000184	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—skin cancer	4.15e-06	0.000178	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—skin cancer	3.97e-06	0.000171	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—skin cancer	3.8e-06	0.000163	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—skin cancer	3.64e-06	0.000156	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—skin cancer	3.48e-06	0.00015	CbGpPWpGaD
